An interventional study of Hesperidin in Cognitive Dysfunction and Overweight and Obesity, sponsored by Min Hou. Recruiting at 1 site in China. Open to participants aged 55 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-08-06.
Sponsored by Min Hou · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 310 studies in Cognitive Dysfunction with a site in China — 144 open to participants now, 156 under way, 8 of them phase 3. Cognitive Dysfunction · China.
Among the 310 studies in Cognitive Dysfunction with a site in China, this one is the 99th largest by planned enrollment of the 191 interventional ones that give a count, is one of 45 that started in 2026, is one of 139 with no phase, reaches primary completion later than 88 of the 155 other live ones, and was the 287th registered.
3,883 studies on the registry are indexed under Cognitive Dysfunction; 1,121 are open to participants now.
Browse Cognitive Dysfunction studies →144 of the 310 studies in Cognitive Dysfunction with a site in China are open now. Recruiting first, the newest first:
Central South University · Sites in China
Ages 18–35
Shanghai University of Sport · Sites in China
Ages 60–80
First Teaching Hospital of Tianjin University of Traditional Chinese Medicine · Sites in China
Ages 35–80
Beijing Tiantan Hospital · Sites in China
Ages 12–70
Shanghai University of Sport · Sites in China
Ages 65+
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 752 Cognitive Dysfunction studies recruiting now, 362 (48%) set no upper age limit and 144 (19%) stop at 75 or younger; 46 take children under 18; 260 take healthy volunteers.
This study: 55 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
310 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 7 · Phase 2 24 · Phase 3 17 · Phase 4 15
First in 2000; this study’s year is marked. 45 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 105 is above the median of 64 across 2,802 interventional studies indexed under Cognitive Dysfunction.
Median enrollment 110 across the 191 interventional studies, 300 across the 119 observational. Of the 90 that completed or were terminated, 3 (3%) have results posted.
This tab as a report to print or save as PDF → With an account.
16 of 310 have an industry lead sponsor. The 10 most frequent:
This is the only study on the registry with Min Hou as lead sponsor.
Min Hou has 1 study filed under Cognitive Dysfunction — fewer than ten, so there is no comparison to draw.
34 of the studies in Cognitive Dysfunction with a site in China that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03887455Phase 3Eisai Inc.A Study to Confirm Safety and Efficacy of Lecanemab in Participants With Early Alzheimer's Disease | 2026-12-31 |
| NCT07603102Nanjing Mingzhou Rehabilitation HospitalMindfulness With Dual-Task Training in Post-Stroke Mild Cognitive Impairment | 2026-11 |
| NCT06417086ZhanYJClinical Evaluation of Acupuncture Treatment on Alzheimer's Disease in APOE e4 Carriers and Non-Carriers | 2026-11-30 |
| NCT07760415Xiangya Hospital of Central South UniversityEEG Changes and Cognitive Profiles in Sepsis Patients With Different Inflammatory Phenotypes | 2026-12-12 |
| NCT03810794Jian Pei,MDClinical Evaluation on the Therapeutic Effect of Acupuncture Treatment for Alzheimer's Disease | 2026-12-30 |
Add all 34 to your calendar (.ics) → With an account.
Among the 310 studies in Cognitive Dysfunction with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
A randomized, double-blind, placebo-controlled trial was designed to test whether two doses of hesperidin (a natural flavonoid from citrus fruits) improve cognitive function in overweight and obese older adults.
A total of 105 participants, aged 55-75 years with a BMI ≥24 kg/m² or elevated waist circumference, will be randomly assigned to one of three 10-week treatments: placebo, low-dose hesperidin (300 mg/day), or high-dose hesperidin (600 mg/day).
The primary aim is to see if hesperidin supplementation enhances cognitive performance - specifically executive function, memory, and attention - and to explore any dose-response relationship.
Secondary aims include examining changes in gut microbiota composition and related metabolites, as well as exploring potential mechanisms behind any observed effects.
The findings are expected to provide scientific evidence on whether hesperidin could serve as a nutritional strategy to support cognitive health in this population.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
MMSE and MoCA
Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants receive 2 placebo capsules (corn starch 600 mg/day) daily for 10 weeks. Capsules are identical in appearance, smell, and packaging to hesperidin capsules.
Dietary Supplement: Hesperidin
Participants receive hesperidin 300 mg + corn starch 300 mg (total 600 mg) daily, taken as 2 capsules for 10 weeks.
Dietary Supplement: Hesperidin
Participants receive hesperidin 600 mg daily, taken as 2 capsules for 10 weeks.
Dietary Supplement: Hesperidin
Oral hesperidin supplementation or matching placebo, administered as 2 capsules per day for 10 weeks. * Placebo Comparator: corn starch 600 mg/day * Low-dose: hesperidin 300 mg + corn starch 300 mg/day (total 600 mg) * High-dose: hesperidin 600 mg/day All capsules are identical in appearance, color, smell, taste, and packaging to maintain blinding. All participants undergo scheduled assessments: physical measurements (weeks 2,4,6,8), 24h dietary recall and IPAQ (every 2 weeks), weekly urine samples, fecal samples (weeks 2,4,8,10), fasting blood samples (baseline and week 10), and bi-weekly nutrition education lectures (general health education only ,no dietary restriction).
Also known as: Citrus Flavonoid
Change in Cognitive Function Assessed by the Mini-Mental State Examination (MMSE)
Units on a Scale (0 to 30 points).Higher scores indicate better cognitive function. Scores ≥25 are generally considered normal; scores \<24 suggest cognitive impairment.
Time frame: Baseline to Week 10
Change in Cognitive Function Assessed by the Montreal Cognitive Assessment (MoCA)
Units on a Scale (0 to 30 points).Higher scores indicate better cognitive function. Scores ≥26 are considered normal; scores 18-25 indicate mild cognitive impairment; scores 10-17 indicate moderate impairment; scores \<10 indicate severe impairment.
Time frame: Baseline to Week 10
Change in Cognitive Function Assessed by the Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-Cog)
Units on a Scale (0 to 30 points). Higher scores indicate worse cognitive function (greater impairment).
Time frame: Baseline to Week 10
Change in Cognitive Function Assessed by the Trail Making Test (TMT)
Unit of Measure is Seconds. Shorter completion times indicate better cognitive function. Part B assesses executive function and cognitive flexibility; a higher TMT-B/TMT-A ratio may indicate greater impairment.
Time frame: Baseline to Week 10
Change in Cognitive Function Assessed by the Digit Symbol Substitution Test (DSST)
Unit of Measur is Number of correct responses. Higher scores indicate better processing speed, sustained attention, and working memory.
Time frame: Baseline to Week 10
hange in Cognitive Function Assessed by the Wechsler Memory Scale (WMS)
Raw scores for each subtest are converted to scaled scores using norm tables; scaled scores are summed to obtain the full-scale score, which is then converted to a Memory Quotient (MQ) using norm tables.Higher scores indicate better memory function. The Memory Quotient (MQ) normally ranges from 80 to 120. Scores below 80 suggest below-average memory performance; scores above 120 suggest above-average memory performance.
Time frame: Baseline to Week 10
Change in Gut Microbiota Composition
Changes in gut microbiota composition and diversity assessed by 16S rRNA sequencing or metagenomic analysis of fecal samples. Primary focus on alpha and beta diversity, and relative abundance of key bacterial taxa (e.g., Bifidobacterium, Lactobacillus, Akkermansia).
Time frame: Baseline to Week 10
Change in Inflammatory Markers (TNF-α, IL-6, CRP)
Changes in serum levels of pro-inflammatory markers including tumor necrosis factor-alpha (TNF-α), interleukin-6 (IL-6), and C-reactive protein (CRP), measured by ELISA or multiplex assays.
Time frame: Baseline to Week 10
Change in Body Weight
Change in body weight measured using standard anthropometric procedures, reported in kilograms (kg); reduction indicates improvement in weight status.
Time frame: Baseline to Week 10
Change in Waist Circumference
Change in waist circumference measured using standard anthropometric procedures at the midpoint between the lowest rib and the iliac crest, reported in centimeters (cm); reduction indicates improvement in central adiposity.
Time frame: Baseline to Week 10
Change in Body Mass Index (BMI)
BMI calculated as body weight in kilograms divided by the square of height in meters (kg/m²). Height was measured at baseline only using standard anthropometric procedures. Reduction in BMI indicates improvement in overall adiposity. Per Chinese BMI classification standards: 24.0-27.9 kg/m² (overweight) and ≥28.0 kg/m² (obese); the study enrolled participants with BMI ≥ 24.0 kg/m².
Time frame: Baseline to Week 10
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Started Feb 2026 (actual). Primary completion is estimated for Mar 2027, 13 months after the start.
Of 1,452 non-industry interventional studies with no phase under Cognitive Dysfunction, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 51. This study's planned 13 months is below that.
Counting every sponsor, half of 1,521 studies reached it within 27 months; a quarter within 12 and three quarters within 50.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Hesperidin